To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Bicifadine is a serotonin-norepinephrine reuptake inhibitor (SNRI) developed by DOV Pharmaceutical. It has been developed as an analgesic and is currently under development for the treatment of various pain conditions. Phase III trials were completed in 2006 for treating chronic low back pain, and the drug is currently being tested to assess its efficacy in treating pain associated with osteoarthritis, acute post-surgical pain, neuropathic pain and pain associated with dental surgery.
Additional recommended knowledge
Bicifadine represents a novel class of drug using a non-opioid, non-NSAID mechanism for the treatment of pain, which should have less abuse potential than opioid drugs. It is not the first SNRI used for pain treatment, as the older drug duloxetine has previously been approved for the treatment of neuropathic pain, and also some atypical opioid drugs such as tramadol and the newer agent tapentadol exhibit some reuptake inhibition properties that contribute to their therapeutic effects.
Preliminary results suggest that bicifadine has an analgesic efficacy slightly stronger than codeine and approximately equivalent to tramadol, although side effects such as nausea and headache were more common with bicifadine than with tramadol.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Bicifadine". A list of authors is available in Wikipedia.|